VIRP Virbac SA

Virbac : Declaration of the number of share and voting rights 05/2025

Virbac : Declaration of the number of share and voting rights 05/2025

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS

Information on the total number of voting rights and of shares representing the share capital

(Article 223-16 of the General regulations of the French Financial Market Authority – Autorité

des Marchés Financiers)

Quotation place: Euronext Paris

Compartiment A

ISIN code: FR0000031577

DateTotal number of shares representing the share capitalTotal number of voting rights
May, 31 20258 390 660Gross total of voting rights : 12 705 976
Net total* of voting rights : 12 693 140

Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights.

VIRBAC: Shaping the future of animal health

NYSE Euronext - Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRP

Corporate Finance: tel. 33 4 92 08 71 32 / Email:

Website:

Attachment



EN
10/06/2025

Underlying

VIRPVirbac SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Virbac SA

 PRESS RELEASE
Free
VIRP VIRBAC SA

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.We are delighted to announce the acquisition of an innovative drug from Norbrook to stabilize feline hyperthyroidism. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) b...

6h / 47m 1 EN
 PRESS RELEASE
Free
VIRP VIRBAC SA

VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm

VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm Cette acquisition apporte à Virbac un produit de spécialité de premier plan, sur un segment en croissance, pour améliorer la qualité de vie des chats âgés.Nous sommes ravis d'annoncer l'acquisition auprès de Norbrook d’un médicament innovant pour stabiliser l'hyperthyroïdie féline. Virbac assurera la distribution directe de ce traitement sous la marque Thyronorm au Royaume-Uni, en Australie et Nouvelle-Zélande ainsi qu’aux États-Unis sous la marque Felanorm,. En Europe, la distribution restera gérée par Boehringer Ingelheim et Elanco...

6h / 47m 1 EN
Aurelien Sivignon ... (+2)
  • Aurelien Sivignon
  • Yan Derocles
UNIQA INSURANCE GROUP AG
VIRP VIRBAC SA
VETO VETOQUINOL SA
CICN CICOREL HOLDING S.A.
ONTEX ONTEX GROUP N.V.
TUI TUI AG
EXENS EXOSENS
12/11/25 December 11, 2025 1 EN
Jean Danjou
  • Jean Danjou
ADP AEROPORTS DE PARIS SA
DB1 DEUTSCHE BOERSE AG
PUM PUMA SE
ROG ROCHE HOLDING LTD
CBK COMMERZBANK AG
AFX CARL ZEISS MEDITEC AG
FHZN FLUGHAFEN ZURICH AG
VIRP VIRBAC SA
VETO VETOQUINOL SA
EOAN E.ON SE
BC BRUNELLO CUCINELLI S.P.A.
ALC ALCON INC.
12/11/25 December 11, 2025 1 EN
Aurelien Sivignon ... (+2)
  • Aurelien Sivignon
  • Yan Derocles
UNIQA INSURANCE GROUP AG
VIRP VIRBAC SA
VETO VETOQUINOL SA
CICN CICOREL HOLDING S.A.
ONTEX ONTEX GROUP N.V.
TUI TUI AG
EXENS EXOSENS
12/11/25 December 11, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch